AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02772926 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Benfotiamine
Description: Benfotiamine (S-Benzoylthiamine O-monophosphate) 900 mg per day
Study NCT02772926 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 900 mg per day
Study NCT01473823 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 LCPUFA
Description: Dosage is 5 ml daily until age 3 years.
Study NCT01473823 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Omega-3 LCPUFA
Description: Dosage is 5 ml daily until age 3 years.
Study NCT00556946 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Combined Photodynamic & Pulsed Dye Laser Treatment
Description: Treatment of Port Wine Stains using Combined Photodynamic and Pulsed Dye Laser
Study NCT02321657 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iPad app containing art, music and games
Description: An iPad app that takes demographic information on a child and suggests suitable art, music and games for use by the anaesthetist and nurse to distract them during anaesthetics
Study NCT02321657 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Toys, books and games
Description: Games, books and toys used to distract
Study NCT02283424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: compared with chemotherapy,which is better for lung adenocarcinoma patients with epidermal growth factor receptor gene mutation after surgery
Study NCT02283424 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Icotinib
Description: compared with chemotherapy,which is better for lung adenocarcinoma patients with epidermal growth factor receptor gene mutation after surgery
Study NCT02283424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy (Carboplatin and Docetaxel)
Description: as control group,compared with Icotinib
Study NCT02283424 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy (Carboplatin and Docetaxel)
Description: as control group,compared with Icotinib
Study NCT01537601 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Circumcision
Description: Circumcision
Study NCT01537601 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Antibiotic prophylaxis alone
Description: Antibiotic prophylaxis alone
Study NCT00598741 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DCE-MRI
Description: Patients will undergo DCE-MRI prior to, and within 18-24 days of starting chemotherapy. These studies are designed to determine if the DCE-MRI data will provide an a priori or early prognostic marker of tumor response. The dynamic MRI is done on a standard clinical scanner using standard techniques described below.~MR imaging studies will be acquired on a 1.5T GE (Milwaukee,WI) Signa LX scanner.
Study NCT00730483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PVA microporous hydrospheres/doxorubicin hydrochloride
Study NCT02597504 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pen and paper neuropsychological test
Description: Will be administered for Construct Validity to determine agreement with Quick Test
Study NCT02597504 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Quick Test
Description: Quick Test, computerized test will be administered to all subjects.
Study NCT02597504 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Quick Test
Description: Quick Test, computerized test will be administered to all subjects.
Study NCT03187301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-130277
Description: APL-130277 single dose
Study NCT03187301 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo single dose
Study NCT02300376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dosage of Calcium edetate de sodium
Description: There is no medical data for the use of Calcium edetate de sodium as a tracer to assess GFR. Calcium edetate de sodium is a treatment for lead intoxication. The extension of use as a tracer comes from its exclusive elimination by glomerular filtration. Plasma and renal clearance of Calcium edetate de sodium and Inulin will be measured for every included patient during a hospital day care (V1). For transplanted patients, plasma clearance of Calcium edetate de sodium will be repeated within one week (more or less 48hours) during annual medical check-up of renal transplantation.
Study NCT04292574 — intervention group
Intervention type: OTHER
Intervention: Patient Registry
Description: Participants who have volunteered to participate will complete various questionnaires relating to their conditions.
Study NCT04330300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiazide or Thiazide-like diuretics
Description: Anti-hypertensive (Active Arm)
Study NCT03187301 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: moxifloxacin 400mg single dose
Study NCT02647957 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Code Stroke
Description: Apply a protocol called Code Stroke that involves the entire care chain from emergency teams outpatient specialists of Neurology, Internal Medicine, Radiology or Intensitivos Care, among other hospital areas.
Study NCT03390751 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: The collection of data will be done by interrogation of the patient and his family / entourage and rereading of medical records
Study NCT02498704 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: Trigger point dry needling to hamstring muscle group.
Study NCT02498704 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Needling
Description: Superficial palpation of trigger point, skin is not punctured.
Study NCT02992041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VVZ-149 Injections
Description: IV infusion of 900 or 1100 mg of VVZ-149
Study NCT04330300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Channel Blockers
Description: Anti-hypertensive (Active Arm)
Study NCT04330300 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACE inhibitor
Description: Anti-hypertensive (Control Arm)
Study NCT04330300 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Angiotensin receptor blocker
Description: Anti-hypertensive (Control Arm)
Study NCT04450290 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CIDEXEL implant
Description: The newly developed MED-EL Cochlear Implant incorporates the anti-inflammatory agent dexamethasone (DEX) into the electrode array. The passive elution of DEX during the post-implantation period has the purpose of counteracting the increase of the post-operative impedance induced by the insertion trauma.
Study NCT01718054 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vascular ready-to-use supplementary food
Description: Daily vascular ready-to-use supplementary food containing protein, energy and fortified with 1 x recommended daily allowance(RDA) of vitamins and minerals except for folic acid = 1mg and with no iron fortificant included and fortified with arginine and citrulline amino acids
Study NCT01718054 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Regular Ready-to-use supplementary food
Description: Daily ready-to-use supplementary food containing protein, energy and fortified with 1 x RDA vitamins and minerals except for folic acid = 1mg and with no iron fortificant included.
Study NCT01718054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Study NCT02902731 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: subcutaneous injection of placebo every day during 16 weeks
Study NCT02902731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANAKINRA
Description: subcutaneous injection of anakinra every day during 16 weeks
Study NCT02693184 — intervention group
Intervention type: OTHER
Intervention: Full length Block 2014 Food Frequency Questionnaire
Description: The food and beverage list includes 127 items, plus additional questions to adjust for fat, protein, carbohydrate, sugar, and whole grain content.
Study NCT02693184 — intervention group
Intervention type: OTHER
Intervention: Revised Calcium, Vitamin D and Protein Screener
Description: The food list includes 29 food items and 5 supplements
Study NCT01993394 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hypergravity
Description: 1hr sitting rest followed by 10 min of hypergravity (2 centrifuge runs)
Study NCT01993394 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gas mixture
Description: breathing air, 44.5%O2 or 100%O2
Study NCT03063632 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interferon Gamma-1b
Description: Given SC
Study NCT03063632 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Ancillary studies
Study NCT03063632 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT02688127 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tranexamic Acid
Description: tranexamic acid or placebo are given before cesarean section in patient with placenta previa
Study NCT02688127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: tranexamic acid or placebo are given before cesarean section in patient with placenta previa
Study NCT05448859 — intervention group
Intervention type: PROCEDURE
Intervention: intracytoplasmic sperm injection
Description: injection of sperm into an oocyte in assisted reproductive technology
Study NCT01181856 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA 85A
Description: Single injection of 1 x 108 pfu MVA85A
Study NCT02657993 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: The hypnosis intervention involves three parts. First, participants will receive three, face-to-face hypnosis sessions delivered by doctoral-level psychology professionals. The sessions are based on materials developed by experienced psychologists in the Integrative Behavioral Medicine Program at the Icahn School of Medicine at Mount Sinai. Second, participants will be taught how to use hypnosis themselves (self-hypnosis) to help manage their pain. Third, participants will receive a hypnosis recording to listen to in-between sessions and throughout the course of the study. At home hypnosis practice will be recommended.~Participants will be asked to complete questionnaires over a period of 12 months.
Study NCT02657993 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: The attention control intervention involves three face-to-face meetings with a doctoral-level psychology professional. During these sessions, participants will be asked to discuss with the interventionist their experience of taking aromatase inhibitors and associated musculoskeletal pain. The interventionist will not lead the patient in imagery, relaxation, evaluation of thought processes, or even simple discussion. Rather interventionists will allow the patient to direct the flow of the conversation and will provide support and empathy. Interventionist contact time in AC sessions will be identical to that in the hypnosis group. Overall, the attention control intervention will control for professional attention.~Participants will be asked to complete questionnaires over a period of 12 months.
Study NCT04083339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-001
Description: AT-001 will be administered as 3 capsules twice daily, before breakfast and before dinner.~At present AT001 is the sole name for the active substance. No INN/genetic name is available to date
Study NCT04083339 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered as 3 capsules twice daily, before breakfast and before dinner
Study NCT01916564 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Split-dose
Description: 2 tablets of bisacodyl 5 mg at 8 p.m. two days before colonoscopy~Low fibre diet and 2 tablets of bisacodyl 5 mg at 8 p.m. on the day before colonoscopy~1-L PEG-ELS between 8 p.m. and 8.30 p.m. on the day before and 1-L PEG-ELS between 5.30 a.m. and 6 a.m. on the day of colonoscopy
Study NCT01916564 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Same-morning whole-dose
Description: 2 tablets of bisacodyl 5 mg at 8 p.m. two days before colonoscopy~Low fibre diet and 2 tablets of bisacodyl 5 mg at 8 p.m. on the day before colonoscopy~2-L PEG-ELS between 5 a.m. and 6 a.m. on the day of colonoscopy
Study NCT01665053 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PROMUS Element Plus
Description: A drug eluting coronary stent system
Study NCT01665053 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SYNERGY
Description: A drug eluting coronary stent system
Study NCT00548990 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cardiovascular exercise training
Study NCT00548990 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: flexibility/balance control
Study NCT00564174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin and low dose aspirin
Description: Fragmin 5000 IU/day by subcutaneous injection started at time of randomization and continued until 35 weeks gestation or delivery and low dose aspirin 81 mg/day started pre-conception and continued until 35 weeks gestation or delivery
Study NCT00564174 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dose aspirin
Description: 81 mg enteric coated started pre-pregnancy and discontinued at 35 weeks or delivery
Study NCT04582227 — intervention group
Intervention type: DEVICE
Intervention: Ambu aura-i LMA
Description: The ETT or the LMA will be inserted with the patient's head position is aided either by pins or head rest, and either the head will be in neutral position or tilted as long as the airway device is successfully placed.
Study NCT03212105 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Educational Brochure
Description: The educational pamphlet will contain information about pain and stress, which patients will be able to read within 60 seconds.
Study NCT00560183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Q8003 (morphine sulfate and oxycodone hydrochloride)
Description: Capsules, four different mg dosage strengths
Study NCT00560183 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules
Study NCT01847183 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Click City®: Alcohol
Description: A school based program, Click City®: Alcohol consists of 12 effective components delivered in 7th grade and a booster of 5 effective components delivered in 8th grade.
Study NCT00303992 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Study NCT00303992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Study NCT01092520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Day 1 - 5mg/kg/dose per os at bedtime then 5mg/kg/dose PO b.i.d x 1 day (Day 2) then on Day 3, 5mg/kg/dose PO t.i.d . x 19 days; after 7 days, if not at maximal effect may increase over 3 days to 10mg/kg/dose (Day 8: 5 mg/kg/dose q.am and midday, Day 9: 10mg/kg/dose b.i.d. + 5mg/kg/dose midday, Day 10: 10mg/kg/dose t.i.d.) Doses may be reduced if patient experiences intolerable side effects.
Study NCT02139345 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TC-A PS Total Knee Replacement System
Description: Subject will be implanted with the TC-A PS Total Knee Replacement System
Study NCT02139345 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TC-PLUS Solution PS Total Knee Replacement System
Description: Subject will be implanted with the TC-PLUS Solution PS Total Knee Replacement System
Study NCT03970447 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Dosage Form: Capsule for oral administration Strengths: 5 mg, 20 mg, 100 mg, 140 mg, 180 mg, or 250 mg
Study NCT03970447 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lomustine
Description: Dosage Form: Capsule for oral administration Strength: 5 mg, 10 mg, 40 mg, and 100 mg
Study NCT03970447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Dosage Form: Tablet for oral administration Strength: 40 mg Standard Regimen: 160 mg orally (PO) every day (QD) for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)
Study NCT03970447 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation
Description: 60 Gy
Study NCT02992041 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion of 0 mg of VVZ-149
Study NCT01357317 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet counseling
Description: If serum phosphorus level exceeds 4.6 mg/dl in the lanthanum carbonate arm in spite of consecutive up-titration of the medical dose or due to patients' intolerance of the medication, patient will be considered a treatment failure and other treatment options will be implemented, including diet counseling or another class of phosphorus binder (in this order of preference).
Study NCT01357317 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet counseling
Description: If serum phosphorus level exceeds 4.6 mg/dl in spite of consecutive up-titration of the medication dose or due to patients' intolerance of the medication, patient will be considered a treatment failure and other treatment options will be implemented, including diet counseling or another class of phosphorus binder (in this order of preference).
Study NCT01357317 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phosphorus binder
Description: If serum phosphorus level exceeds 4.6 mg/dl after 3 months of concerted efforts, the patient will be considered a treatment failure and treatment with a phosphorus binder of the treating physician's choice will be allowed.
Study NCT05989360 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lung Clearance Index
Description: Normative values in healthy children from ethnic backgrounds
Study NCT00006081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bryostatin-1
Description: 40 mcg/m2 one-hour infusion 24 hours after each dose of paclitaxel (i.e., day 2, 9, 16).
Study NCT00006081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel (Taxol)
Description: 80 mg/m\^2 one-hour infusion weekly x 3 every 4 weeks
Study NCT02197728 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Use of the Colpo-Probe™ Vaginal Fornix Delineator or Hohl manipulator® during total laparoscopic hysterectomy
Study NCT01162590 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix ™
Description: Oral, single dose
Study NCT01162590 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral, single dose
Study NCT02277314 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Manual Small Incision Cataract Surgery
Description: This cost-effective solution for removing cataracts, also known as Manual Small Incision Cataract Surgery (MSICS), is a positive alternative when Phaco is not an option due to costs. The procedure takes approximately 30 minutes and involves a mid-size incision and an intraocular lens (IOL), or artificial lens, replacing the natural lens. Following the procedure, patients may need glasses, and most will need bifocals, but overall vision will be significantly improved.
Study NCT01133392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin lispro A
Description: 20 units (U) subcutaneously (SC).
Study NCT01133392 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin lispro B
Description: 20 U subcutaneously (SC).
Study NCT00686374 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Participants who enrolled into the study from blinded therapy in Study M06-806 received open-label (OL) therapy at a dose dependent on their body weight. Participants weighing ≥ 40 kg received 40 mg of adalimumab every other week (eow), and those who weighed \< 40 kg received 20 mg of adalimumab eow. Starting at Week 8, participants who had a disease flare may have been switched to every week (ew) treatment at the same dose of adalimumab received while on eow treatment. Participants who enrolled from OL therapy in Study M06-806 continued to receive the same dose they were receiving (i.e., 40 mg ew or 20 mg ew) at the Week 52 visit of Study M06-806. Adalimumab dose could have been decreased to the next lower treatment level for those with body weight changes. Participants who responded to treatment may have also had their dosage frequency decreased from ew to eow dosing, as well as a decrease in dosage.
Study NCT03425591 — intervention group
Intervention type: DRUG
Intervention: Ibrutinib
Description: Participants in this observational study with confirmed diagnosis of CLL and MCL receiving ibrutinib in routine clinical practice settings will be observed for 5 years.
Study NCT03549130 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breathe Right Tan (small/medium) nasal strips
Description: Participants of this treatment arm applied sufficient quantity of commercially available nasal strips (Breathe Right Tan), small/medium sized outside of the nose, from alar crease to alar crease, as per dispensing instructions, prior to sleeping. Participants used their assigned strip every night, for approximately 8 hours, but no more than 12 hours per night, for two weeks